Outcomes by CAR product	All patients intended for outpatient administration (n=64)			
CRS	80% (51, all grade 1-2)			
• Axi-cel (22)	82% (18)			
• Brexu-cel (2)	100% (2)			
• Liso-cel (5)	80% (4)			
• Tisa-cel (1)	100% (1)			
• Ide-cel (10)	100% (10)			
• Cilta-cel (24)	67% (16)			
ICANS	31% (20 grade 1-2=9, grade 3-4=11)			
• Axi-cel (22)	50% (11, grade 1-2=4, grade 3-4=7)			
• Brexu-cel (2)	50% (1, grade 4)			
• Liso-cel (5)	20% (1, grade 3)			
• Tisa-cel (1)	100% (1, grade 1)			
• Ide-cel (10)	30% (3, grade 1-2=1, grade 3-4=2)			
• Cilta-cel (24)	12.5% (3, all grade 1-2)			
30-day Admissions	Total	Days 0-3	Days 4-7	Days 8-30
• Axi-cel (22)	14	6	7	1 (2 readmissions)
• Brexu-cel (2)	2	0	2	0
• Liso-cel (5)	4	2	2	0
• Tisa-cel (1)	1	1	0	0
• Ide-cel (10)	7	6	1	0 (1 readmission)
• Cilta-cel (24)	14	2	4	8 (1 readmission)

Supplementary Table 1: Rates of CRS, ICANS and admission in the different CAR T-cell products

Abbreviations: Axi-cel, axicabtagene ciloleucel; Liso-cel, lisocabtagene maraleucel; Brexu-cel, brexucabtagene autoleucel; Cilta-cel, ciltacabtagene autoleucel; Ide-cel, idecabtagene vicleucel; Tisa-cel, tisagenlecleucel, FluCy, fludarabine and cyclophosphamide; CRS, cytokine release syndrome; ICANS, Immune effector cell-associated neurotoxicity syndrome

Historical control baseline characteristics	Patients with inpatient cell infusion (n=24)
Median age (range)	67 (23-78)
Female	39% (9)
Histology • Aggressive B-cell lymphoma • Mantle cell lymphoma • Myeloma	 83.3% (20) 8.3% (2) 8.3% (2)
• Median prior lines of therapy (range)	4 (2-7)
Type of CAR • Axi-cel • Tisa-cel • Liso-cel • Brexu-cel • Ide-cel	 13 5 2 2 2
Lymphodepletion • Flu-Cy	 100% (24)

Supplementary Table 2: Baseline characteristics of patients who received inpatient CAR T-cell therapy between 2020-2021

Abbreviations: Axi-cel, axicabtagene ciloleucel; Liso-cel, lisocabtagene maraleucel; Brexu-cel, brexucabtagene autoleucel; Cilta-cel, ciltacabtagene autoleucel; Ide-cel, idecabtagene vicleucel; Tisa-cel, tisagenlecleucel, Flu-Cy, fludarabine and cyclophosphamide.